MENLO PARK, Calif., June 12 (UPI) -- A U.S. Food and Drug Administration Phase 3 study indicates Glumetza -- a drug to be launched this summer-- improves upon the diabetes drug metformin.
The pharmaceutical company Depomed Inc., makers of Glumetza, said metformin is one of the most common type 2 diabetes drugs, yet 60 percent of patients stop taking it as prescribed within the first year, mainly because of side effects such as nausea and diarrhea.
Advertisement
In the Phase 3 trial, Depomed said Glumetza had 97 percent patient compliance because of its formulation that allows for once-daily dosing, excellent tolerability, and better efficacy at high doses.
The results of the second Phase 3 clinical trial appear in the June issue of the journal Diabetes.
